Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%
Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that can shift short‑term price action, especially given the lowered EBITDA outlook.
Market read
First report of HIMS Q3 results; material numbers and guidance change create immediate trading relevance.
What to watch
Potential cost efficiencies from scale and upcoming product launches not reflected in current guidance.
Background
Hims & Hers Health (HIMS) reported Q3 2026 results with significant revenue growth but weaker profitability.
Ticker impact
Quarterly earnings release showing 49% revenue growth, margin compression and lowered full-year EBITDA guidance.
likely near‑term volatility with pressure on the stock as investors weigh strong top‑line against weaker profitability and guidance.
Revenue beat is positive, but 17‑point margin drop and reduced EBITDA outlook may trigger sell‑side pressure.
Market effects
Telehealth and digital health sector may see heightened scrutiny on margins as growth accelerates.
U.S. market participants focused on earnings; limited broader regional effect.
Limited to investors tracking U.S. telehealth stocks.
Counterpoint
Margin compression could be temporary; focus on revenue momentum may support upside.
Key entities
- companyHims & Hers Health
U.S.-listed telehealth provider.
- executiveYemi Okupe
Chief Financial Officer of Hims & Hers.
